Nevus Clinical Trial - A Trial to Investigate Scar Improvement Efficacy of

Status Active, not recruiting

Clinical Trial Summary

This trial will investigate whether four doses of RN1001 (20ng, 50ng, 100ng and 200ng) are efficacious in preventing or reducing the resultant scar, as compared to placebo, when applied intradermally to wound margins following excision of benign naevi situated on the head and neck.

Clinical Trial Description

Male and female subjects (aged between 18-85 years) with one or more benign head & neck naevi will be invited to participate in the study.

Each patient will be randomised to a particular dose group, depending on the number of naevi suitable for excision. For example, patients with one excised naevi will receive either a dose of one of the concentrations of RN1001, or placebo. A patient with 2 excised naevi will receive an active dose, and placebo. Patients with 3 excised naevi will receive 2 active doses, plus placebo, and patient with four excised naevi will receive 3 active doses plus placebo.

Naevi will be excised using punch biopsy, and then closed with standard sutures. Following wound closure, the study drug (active RN1001 or placebo) will be administered via intradermal injection at a rate of 100ul per linear cm of wound margin.

Digital and film photography will be taken pre-dose and post dose (Day 0, day 14, day 28, Month 2, 3, 6 & 12, and thereafter at M24, M36, M48 & M60). Additionally, scar assessments (completed by Investigator, Research Nurse & Medical photographer) will be completed at follow up visits from Day 20 onwards. Silicone moulds of the scars will be taken at M6, M12 and then annually to M60.

Patients will be requested to complete a questionnaire to rate their scar expectations/assessment on a total of 5 occasions (screening, Day 0, Month 3, Month 6 & Month 12) ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00656227
Study type	Interventional
Source	Renovo
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 2004
Completion date	July 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02645773` - Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring	N/A
Completed	`NCT02672956` - Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results	N/A
Completed	`NCT00629811` - Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women	Phase 2
Completed	`NCT00847795` - Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.	Phase 1/Phase 2
Completed	`NCT00977951` - Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects	Phase 1/Phase 2
Not yet recruiting	`NCT03213548` - Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty	N/A
Recruiting	`NCT05377723` - Abdominal Scar Improvement in Microsurgical Breast Reconstruction	N/A
Active, not recruiting	`NCT01976260` - A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars	N/A
Terminated	`NCT00432328` - Juvista (Avotermin) in Breast Reduction Surgery Scars	Phase 2
Completed	`NCT00594581` - Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males	Phase 2
Completed	`NCT00984503` - Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites	Phase 2
Recruiting	`NCT04420442` - Scar Resection and Reconstruction With Integra and Split Skin Grafts in Patients With Non-Suicidal Self-Inflicted Scars	N/A
Completed	`NCT02772289` - Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars	Phase 2
Completed	`NCT00430326` - Juvista (Avotermin) in Scars Following Varicose Vein Removal	Phase 2
Completed	`NCT00847925` - Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects	Phase 1/Phase 2
Recruiting	`NCT05787171` - Three Sutures With Different Absorption Rates for Lower Abdominal Incision	N/A
Completed	`NCT02985151` - Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy	N/A
Completed	`NCT02340325` - FS2 Safety and Tolerability Study in Healthy Volunteers	Phase 1
Active, not recruiting	`NCT00432211` - Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.	Phase 2
Completed	`NCT00978302` - Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms